Details

Autor(en) / Beteiligte

• Barr, Eliav, MD
• Gause, Christine K., PhD
• Bautista, Oliver M., PhD
• Railkar, Radha A., PhD
• Lupinacci, Lisa C., PhD
• Insinga, Ralph P., PhD
• Sings, Heather L., PhD
• Haupt, Richard M., MD, MPH

Titel

Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women

Ist Teil von

• American journal of obstetrics and gynecology, 2008-03, Vol.198 (3), p.261.e1-261.e11

Ort / Verlag

Philadelphia, PA: Mosby, Inc

Erscheinungsjahr

2008

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Objective The purpose of this study was to inform policy regarding human papillomavirus (HPV) vaccination in North America. We measured the clinical impact of HPV-6/-11/-16/-18 vaccination in North American women. Study Design The study enrolled 21,954 women, the majority aged 16-25, across 5 studies of a quadrivalent HPV vaccine or its HPV-16 vaccine prototype. The North American subjects (n = 5996) were pooled from these trials, and the prevalence of HPV-6/-11/-16/-18 exposure was measured. The impact of vaccination on the burden of anogenital HPV lesions in an intention-to-treat population (regardless of enrollment HPV status) was calculated. Results At enrollment, the median age was 20 years; 13% of the women had had a Papanicolaou test abnormality, and 76% of the women had negative tests results for all 4 vaccine HPV types. With approximately 3 years of follow-up evaluations in the intention-to-treat population (regardless of enrollment HPV status), vaccination reduced the rate of HPV-16– and -18–related precancers and HPV-6/-11/-16/-18–related genital lesions by 66.4% (95% CI, 42.7%-81.1%) and 57.7% (95% CI, 27.3%-76.3%), respectively. Conclusion The administration of HPV vaccine to sexually active North American women reduced the burden of HPV-6/-11/-16/-18–related disease. Catch-up vaccination programs in this population are warranted.